Pre-Congress Workshop 2: Designing Human Intervention Studies to Prevent Osteoarthritis After Knee Injury: An Interdisciplinary Workshop

Date/Time: Friday, March 17, 2023 - 10:00 AM to 12:30 PM
Log in to Add to My Schedule


Preventing Post-Traumatic OA Illness and Disease: Vision and Challenges 

What Is Post-Traumatic Osteoarthritis, Who Develops It and What Is the Goal of An Intervention?
Dr. Jackie Whittaker, The University of British Columbia, Canada 

Defining the Best Outcome Measures, Their Timing and Relationships: Symptoms, Structure and Molecules
Prof. Stefan Lohmander, Lund University, Sweden 

Bridging the Gap to Clinical Trials 

Considerations for Post-Traumatic Osteoarthritis: A Regulatory Perspective 
Dr. Lee Simon, SDG LLC, USA 

Can Pre-Clinical Models and Experimental Medicine Studies Help Intervention Selection and Trial Design? 
Dr. Nicole Gerwin, Novartis, Switzerland 

From Around the (Real) World: Current Examples of Trials, Their Interventions and Comparators 

Exercise/Physical Therapy
Dr. Adam Culvenor (SUPER-KNEE), La Trobe University, Australia

Prof. Duncan Meuffels (ROTATE-Trial, COMPARE), Erasmus MC, Netherlands 

Prof. David Felson (PIKASO Trial), Boston University, USA 

Learning Objectives: 

1. Learn about the unmet clinical needs in the period between knee injury and  early post-traumatic knee osteoarthritis (PTOA) 

2. Synthesise the current views on the definition of PTOA 

3. Overview of the different possible aims for interventional studies in this area,  from preventing symptoms and structural change after a knee injury to validating new  targets and surrogate endpoints 

4. Outline different outcome measures that might be applied in different types of studies and the knowledge gaps in this area. 

5. Understand challenges and overarching considerations for approaches to trial design in this area. 

6. Improve knowledge of international efforts (including multicentre studies, networks, and ‘trial banks’) in this area across different intervention types (i.e.  physical therapy, surgical, pharmacological) 

7. Show awareness of key stakeholders in this area (e.g., patients, clinicians,  pre-clinical modelers, pharmaceutical companies, and regulatory bodies)  8. Consider the key priorities for research to enable progress